Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes

PHASE4UnknownINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

April 12, 2019

Primary Completion Date

February 29, 2020

Study Completion Date

February 29, 2020

Conditions
Type2 Diabetes
Interventions
DRUG

Dapagliflozin 10 MG Oral Tablet [Farxiga]

"The investigational medicinal product (IMP) is dapagliflozin10 mg given once daily (film coated tablets, oral use).~Dapagliflozin will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"

DRUG

Placebo Oral Tablet

"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"

Trial Locations (3)

28040

RECRUITING

Hospital Clínico San Carlos, Madrid

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

28046

RECRUITING

Hospital Universitario La Paz, Madrid

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

LM Diagnósticos S.L.

OTHER